Dr. Jain on High-Risk Mutations in Myelofibrosis

Video

In Partnership With:

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Tania Jain, MBBS, assistant professor of oncology, Division of Hematological Malignancies and Stem Cell Transplantation, Johns Hopkins University, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Patients with mutations in ASXL1, EZH2, SRSF2, IDH1/2, and U2AF1 have high-risk myelofibrosis, says Jain. These patients typically have decreased leukemia-free survival and overall survival, explains Jain.

As a result, patients who harbor these mutations may be considered for allogeneic stem cell transplant sooner in their disease course compared with patients without these mutations, concludes Jain.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD